Get started
Author

Jessica Saddi

Observed name: J. Saddi
ORCID: 0009-0004-8176-0737
Observed ORCID: 0009-0004-8176-0737
OpenAlex ID: A5026671626
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk
2018 · Riccardo Caccialanza, Emanuele Cereda, et al. · Supportive Care in Cancer · 48
Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy
2021 · Roberto Mapelli, Chiara Julita, et al. · Strahlentherapie und Onkologie · 9
PDF
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk
2018 · R. Caccialanza, E. Cereda, et al. · Clinical Nutrition · 9
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets
2025 · Francesco Rocco Bertuccio, Simone Montini, et al. · Cancers · 8
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab
2025 · Francesco Cortiula, Talia Shentzer Kutiel, et al. · European Journal of Cancer · 8
PDF
Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review
2022 · Giulia Maria Stella, Filippo Scialò, et al. · Cancers · 6
PDF
Smoking Habit and Respiratory Function Predict Patients’ Outcome after Surgery for Lung Cancer, Irrespective of Histotype and Disease Stage
2023 · Davide Piloni, Francesco R. Bertuccio, et al. · Journal of Clinical Medicine · 5
PDF
Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial
2023 · Andrea Riccardo Filippi, Francesco Agustoni, et al. · Clinical Lung Cancer · 5
Current Treatment Paradigms for Advanced Melanoma with Brain Metastases
2025 · Elisabetta Bonzano, Stefania Barruscotti, et al. · International Journal of Molecular Sciences · 4
PDF
Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI
2025 · Gaia Messana, Chandra Bortolotto, et al. · European Radiology · 3
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before
2024 · Jessica Saddi, Amelia Barcellini, et al. · Hematological Oncology · 3
Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer
2025 · Andrea Lancia, Marco Oderda, et al. · Pharmaceuticals · 2
PDF
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group
2025 · Chiara Catania, Claudia Proto, et al. · Critical Reviews in Oncology/Hematology · 2
125P Preliminary analysis on safety of the DEDALUS phase II trial: Induction chemo-durvalumab followed by reduced-dose radiotherapy and maintenance durvalumab for patients with unresectable stage III NSCLC
2024 · A.R. Filippi, J. Saddi, et al. · ESMO Open · 2
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease
2023 · Francesco Rocco Bertuccio, Francesco Agustoni, et al. · Cancers · 2
PDF
123P Second progression-free survival (PFS2) after first progression in patients receiving PACIFIC regimen: An exploratory analysis of the Blue Sky observational study
2023 · A.R.R. Filippi, J. Saddi, et al. · Journal of Thoracic Oncology · 2
PDF
CT Scan-Guided Fine Needle Aspiration Cytology for Lung Cancer Diagnosis through the COVID-19 Pandemic: What We Have Learned
2023 · Giulia Maria Stella, Vittorio Chino, et al. · Tomography · 2
PDF
Obstructive sleep apnea as a modifier of endocrine toxicities associated with immune checkpoint inhibitors in lung cancer
2026 · Lucrezia Pisanu, Pasquale Tondo, et al. · Frontiers in Immunology · 1
PDF
P2.08.53 Safety Results of DEDALUS Trial: Sequential CT-IO, Hypofractionated RT and Consolidation IO in Unresectable Stage III NSCLC
2025 · F. Agustoni, J. Saddi, et al. · Journal of Thoracic Oncology · 1
Investigation of the ‘New-PDL1’ Delta Radiomic Signature for Identifying Chemo-Radiotherapy Patients Who May Benefit from Consolidation Immunotherapy
2025 · A.R. Filippi, J. Saddi, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
PDF
PD-0962 Second PFS after post-PACIFIC relapse in the Blue Sky observational study on stage 3 NSCLC.
2023 · A.R. Filippi, J. Saddi, et al. · Radiotherapy and Oncology · 1
198TiP DEDALUS trial: A single-arm, phase II, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC
2022 · J. Saddi, F. Agustoni, et al. · Immuno-Oncology Technology · 1
PDF
Radical local treatment for patients with NSCLC following oligoprogression after chemoradiation and durvalumab
2026 · Federico Pravisano, Francesco Cortiula, et al. · European Journal of Cancer
Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial)
2026 · Francesco Agustoni, Jessica Saddi, et al. · JNCI Cancer Spectrum
BRAVE-HEART: Clinical and dosimetric validation of active breath control for cardiac sparing in breast cancer radiotherapy
2026 · E. Bonzano, L. Squillace, et al. · European Journal of Cancer
Works count: 33
Citation count: 125
H-index: 6
I10-index: 1
Year
Topic
Type